Tagged gleolan

Press Release

NX Development Corp. Enrolls First Patient in OVA-302 Study After FDA Orphan Designation for Gleolan®

 Read More
NX Development Corp. is Granted Orphan-Drug Designation Status by US FDA for Gleolan® in Ovarian and Related Cancers
Press Release

NX Development Corp. is Granted Orphan-Drug Designation Status by US FDA for Gleolan® in Ovarian and Related Cancers

 Read More